After promising results from patients enrolled to date, Atossa Therapeutics halted an Australian Phase 2 clinical trial evaluating its investigative oral therapy Endoxifen in women newly diagnosed with invasive, estrogen receptor (ER)-positive breast cancer and scheduled for surgery. “It is a welcome event to halt an ongoing clinical trial because the results are so overwhelmingly positive,” Steven Quay, MD, PhD, Atossa’s president and CEO, said in a press release. Interim data showed that the therapy…
You must be logged in to read/download the full post.
The post ‘Overwhelmingly Positive’ Data Halts Endoxifen Phase 2 Trial for Invasive Cancer appeared first on BioNewsFeeds.